Kenya is set to receive Lenacapavir, a groundbreaking HIV preventive drug that will be administered as an injection just twice a year.

HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study.

A religious movement that has so often taken public stands has been unusually quiet since Trump gutted the program to combat ...

The Global Fund has announced that it signed an access agreement with Gilead Sciences to procure lenacapavir, a twice-a-year injection that has a 99 per cent success rate in preventing HIV ...